APA (7th ed.) Citation

Chen, L., Rangel, J. D. G., Cil, T., Li, X., Cicin, I., Shen, Y., . . . Karaoglu, A. (2023). Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study. Cancer Medicine, 12(22), 20847. https://doi.org/10.1002/cam4.6664

Chicago Style (17th ed.) Citation

Chen, Likun, et al. "Efficacy and Safety of the Proposed Bevacizumab Biosimilar BAT1706 Compared with Reference Bevacizumab in Patients with Advanced Nonsquamous Non‐small Cell Lung Cancer: A Randomized, Double‐blind, Phase III Study." Cancer Medicine 12, no. 22 (2023): 20847. https://doi.org/10.1002/cam4.6664.

MLA (9th ed.) Citation

Chen, Likun, et al. "Efficacy and Safety of the Proposed Bevacizumab Biosimilar BAT1706 Compared with Reference Bevacizumab in Patients with Advanced Nonsquamous Non‐small Cell Lung Cancer: A Randomized, Double‐blind, Phase III Study." Cancer Medicine, vol. 12, no. 22, 2023, p. 20847, https://doi.org/10.1002/cam4.6664.